Skip to content
BillRazor
Generic J9041

BORTEZOMIB 3.5 MG VIAL

Bortezomib 3.5 mg vial has a typical acquisition cost of $43.35, though hospital charges often exceed acquisition costs by 10-20 times or more depending on the facility.

By David Park , Healthcare Cost Researcher · ·
Data from CMS files published FY 2024 CMS IPPS. Refreshed weekly.
About the analyst

David Park researches procedure pricing and insurance reimbursement patterns at BillRazor Research. He specializes in cost comparison across care settings and metropolitan areas. Expertise: procedure pricing, insurance reimbursement, cost comparison.

NADAC acquisition cost data
CMS drug pricing benchmarks
Updated 2026-04-03
Drug acquisition cost — BORTEZOMIB 3.5 MG VIAL
NADAC cost$43.35 per unit
Hospital charges for this drug vary — typically 3–8x the acquisition cost. No observed hospital charge data is available for this specific drug.
$43.35
NADAC acquisition cost
INJECTABLE
Dosage form
INTRAVENOUS, SUBCUTANEOUS
Route

BORTEZOMIB is a cancer medication primarily used for multiple myeloma and mantle cell lymphoma treatment. This generic injectable drug typically requires prior authorization from most insurance plans and charges vary significantly between hospital outpatient departments and physician offices.

Check your bill amount
Enter the charge for BORTEZOMIB 3.5 MG VIAL from your bill to compare against the NADAC acquisition cost.
$

No credit card required. Results in 60 seconds.

Research suggests 49–80% of hospital bills contain errors. Our system checks every line item against Medicare benchmarks.
Rates shown are from the 2026 Medicare Physician Fee Schedule and CMS IPPS. BillRazor compares your bill against these data sources. See how it works →

Data source: National Average Drug Acquisition Cost (NADAC) survey, published by CMS. HCPCS drug pricing codes from Medicare Part B Drug Average Sales Price file.

What NADAC means: The average price pharmacies pay to acquire this drug from wholesalers. Hospital charges for the same drug are typically higher due to facility fees, compounding, and administration costs.

Limitations: NADAC reflects pharmacy acquisition cost, not patient out-of-pocket cost. Insurance copays, formulary tiers, and manufacturer rebates affect what patients actually pay.

Upload your bill — free instant analysis